SEARCH

SEARCH BY CITATION

References

  • Balogh GT, Vukics K, Konczol A, Kis-Varga A, Gere A, Fischer J (2005). Nitrone derivatives of trolox as neuroprotective agents. Bioorg Med Chem Lett 15: 30123015.
  • Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H (1986). Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke 17: 472476.
  • Crossley NA, Sena E, Goehler J, Horn J, Van Der Worp B, Bath PMB et al. (2008). Empirical evidence of bias in the design of experimental stroke studies: a meta-epidemiologic approach. Stroke 39: 929934.
  • Diener HC, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM et al. (2008). NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II Trials. Stroke 39: 17511758.
  • Edenius C, Strid S, Borga O, Breitholtz-Emanuelsson A, Lanbeck Vallén K, Fransson B (2002). Pharmacokinetics of NXY-059, a nitrone-based free radical trapping agent, in health young and eldery subjects. J Stroke Cerebrovasc Dis 11: 3443.
  • Egger M, Davey Smith G, Schneider M, Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. Br Med J 315: 629634.
  • Gibson CL, Gray LJ, Murphy SP, Bath PMB (2006). Estrogen and experimental ischemic stroke: a systematic review. J Cereb Blood Flow Metab 26: 11031113.
  • Gibson CL, Gray LJ, Bath PMW, Murphy S (2007). Progesterone for the treatment of experimental brain injury; a systematic review. Brain 131: 318328.
  • Green AR (2002). NXY-059: Effect in a transient and permanent focal ischemia model in rats. AstraZeneca Internal Report D1550-SP-0001.
  • Green AR (2008). Pharmacological approaches to acute ischaemic stroke: reperfusion certainly, neuroprotection possibly. Br J Pharmacol 153: S325S338.
  • Green AR, Lanbeck-Vallén K, Ashwood T, Lundquist S, Lindström Böö E, Jonasson H et al. (2006). Brain penetration of the novel free radical trapping neuroprotectant NXY-059 in rats subjected to permanent focal ischemia. Brain Res 1072: 224226.
  • Han M, He QP, Yong G, Siesjo BK, Li PA (2003). NXY-059, a nitrone with free radical trapping properties inhibits release of cytochrome C after focal cerebral ischemia. Cell Mol Biol 49: 12491252.
  • Koziol JA, Feng AC (2006). On the analysis and interpretation of outcome measures in stroke clinical trials. Lessons from the SAINT I study of NXY-059 for acute ischemic stroke. Stroke 37: 26442647.
  • Kuroda S, Tsuchidate R, Smith M-L, Maples KR, Siejo BK (1999). Neuroprotective effects of a novel nitrone, NXY-059, after transient focal cerebral ischemia in the rat. J Cereb Blood Flow Metab 19: 778787.
  • Lapchak PA, Araugo DM, Song D, Wei J, Zivin JA (2002a). Neuroprotective effects of the spin trap agent disodium-[(tert-butylimino)methyl] benzene-1,3-disulfonate N-oxide (generic NXY-059) in rabbit small clot embolic stroke model. Combination studies with the thrombolytic tissue plasminogen activitor. Stroke 33: 14111415.
  • Lapchak PA, Araugo DM, Song D, Wei J, Purdy R, Zivin JA (2002b). Effects of the spin trap agent disodium-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) on intracerebral hemorrhage in a rabbit large clot embolic stroke model. Combination studies with tissue plasminogen activator. Stroke 33: 16651670.
  • Lapchak PA, Song D, Wei J, Zivin JA (2004). Coadministration of NXY-059 and tenecteplase six hours following embolic strokes in rabbits improves clinical rating scores. Exp Neurol 188: 279285.
  • Lees KR, Sharma AK, Barer D, Ford GA, Kostulas V, Cheng YF et al. (2001). Tolerability and Pharmacokenetics of the nitrone NXY-059 in patients with acute stroke. Stroke 32: 675680.
  • Lees KR, Barer D, Ford GA, Hacke W, Kostulas V, Sharma AK et al. (2003). Tolerability of NXY-059 at higher target concentrations in patients with acute stroke. Stroke 34: 482487.
  • Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener H-C et al. (2006). NXY-059 for acute ischemic stroke. N Engl J Med 354: 588599.
  • Lyden PD, Shuaib A, Lees KR, Davalos A, Davis SM, Diener H-C et al. (2007). Safety and tolerability of NXY-059 for acute intracerebral haemorrhage. The CHANT Trial. Stroke 38: 22622269.
  • Macleod MR, O'Collins T, Horky LL, Howells DW, Donnan GA (2005). Systematic review and meta-analysis of the efficacy of FK506 in experimental stroke. J Cereb Blood Flow Metab 25: 713721.
  • Macleod MR, Van Der Worp B, Sena ES, Howells DW, Dirnagl U, Donnan GA (2008). Evidence for the efficacy of NXY-059 in experimental focal cerebral ischemia is confounded by study quality. Stroke 39: 28242829.
  • Maples KR (1996). NXY-059 reduces cortical infarct volume when given 30 min after a permanent middle cerebral artery occlusion. Astra Internal Report 805-61 AN 030-31.
  • Maples KR (1997). Estimation of NXY-059 plasma levels following continuous intravenous infusion at 0.30, 3.0, or 30 mg/kg/h. Centaur Internal Report BOR1-R1.
  • Maples KR, Ma F, Zhang YK (2001). Comparison of the radical trapping ability of PBN, S-PBN and NXY-059. Free Radic Res 43: 417426.
  • Marshall JWB, Duffin KJ, Green AR, Ridley RM (2001). NXY-059, a free radical-trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species. Stroke 32: 190198.
  • Marshall JWB, Cummings RM, Bowes LJ, Ridley RM, Green AR (2003). Functional and Histological Evidence for the protective effect of NXY-059 in a primate model of stroke when given 4 hours after occlusion. Stroke 34: 22282233.
  • Schulz KF, Grimes DA (2002). Allocation concealment in randomized trials: defending against deciphering. Lancet 359: 614618.
  • Shuaib A, Lees KR, Lyden P, Grotta J, Davalos A, Davis SMD et al. (2007). NXY-059 for the treatment of acute ischemic stroke. N Engl J Med 357: 562571.
  • Stewart LA, Parmar MK (1993). Meta-analysis of the literature or of individual patient data: is there a difference? Lancet 341: 418422.
  • Strid S, Borga O, Edenius C, Jostell K-G, Odergren T, Weil A (2002). Pharmacokinetics in renally impaired subjects of NXY-059, a nitrone-based, free-radical trapping agent developed for the treatment of acute stroke. J Clin Pharmacol 58: 409415.
  • Stroke Therapy Academic Industry Roundtable (STAIR) (1999). Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 30: 27522758.
  • Sydserff S (2002) NXY-059: effects on infarct volume in a transient middle cerebral artery occlusion model. AstraZeneca Report D1550-SP-0002-01.
  • Sydserff SG, Borelli AR, Green AR, Cross AJ (2002). Effect of NXY-059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat; studies on dose, plasma concentration and therapeutic time window. Br J Pharmacol 135: 103112.
  • Takizawa S, Izuhara Y, Kitao Y, Hori O, Ogawa S, Morita Y et al. (2007). A novel inhibitor of advanced glycation and endoplasmic reticulum stress reduces infarct volume in rat focal cerebral ischemia. Brain Res 1183: 124137.
  • The Optimising Analysis of Stroke Trials (OAST) Collaboration (2007). Can we improve the statistical analysis of stroke trials? Statistical re-analysis of functional outcomes in stroke trials. Stroke 38: 19111915.
  • Wang CX, Shuaib A (2004). NXY-059: a neuroprotective agent in acute stroke. Int J Clin Pract 58: 964969.
  • Williams HE, Claybourn M, Green AR (2007). Investigating the radical trapping ability of NXY-059, S-PBN and PBN. Free Radic Res 49: 10471052.
  • Willmot M, Gray L, Gibson C, Murphy S, Bath PMW (2005a). Systematic review of nitric oxide donors and L-arginine in experimental stroke; effects on infarct size and cerebral blood flow. Nitric Oxide 12: 141149.
  • Willmot M, Gibson C, Gray L, Murphy S, Bath PMW (2005b). Nitric oxide synthase inhibitors in experimental stroke and their effects on infarct size and cerebral blood flow; a systematic review. Free Rad Biol Med 39: 412425.
  • Yoshimoto T, Kanakaraj P, Ma JY, Cheng M, Kerr I, Malaiyandi L et al. (2002a). NXY-059 maintains Akt activation and inhibits release of cytochrome C after focal cerebral ischemia. Brain Res 947: 191198.
  • Yoshimoto T, Kristian T, Hu B, Ouyang Y-B, Siesjo BK (2002b). Effect of NXY-059 on secondary mitochondrial dsyfunction after transient focal ischemia; comparison with cyclosporin A. Brain Res 932: 99109.
  • Zhao Z, Cheng M, Maples KR, Ma JY, Buchan AM (2001). NXY-059 a novel free radical trapping compound, reduces cortical infarction after permanent focal cerebral ischemia in the rat. Brain Res 909: 4650.
  • Zhao Z, Cheng M, Maples KR, Ying Ma J, Buchan AM (2002). Continuous IV infusion of NXY-059 at 120 mg/kg/h fails to achieve expected exposure levels and thus does not reduce cortical infarction after permanent focal cerebral ischemia in the rat. Internal Report to AstraZeneca.